hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-03 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Progesterone is metabolized into allopregnanolone and pregnanolone, which are neurosteroids and potent potentiators of the GABAA receptor. The conversion of progesterone into these metabolites is catalyzed by the enzymes 5α- and 5β-reductase and 3α-hydroxysteroid dehydrogenase, and occurs primarily in the liver, but also occurs in reproductive endocrine tissues, the skin, the brain, and other tissues. Due to extensive first-pass metabolism with oral progesterone, about 80 to 90% or more of progesterone is rapidly transformed into these metabolites, and massive quantities of these neurosteroids are consequently formed and circulate throughout the body and brain. It is for this reason that commonly reported side effects of oral progesterone include dizziness, drowsiness, sedation, somnolence, and fatigue. Both oral and sufficiently high doses of intramuscular progesterone can produce these sedative effects. However, compared to oral progesterone, the levels of these neurosteroids have been found to be very low with parenteral routes like vaginal and intramuscular progesterone. As with the bioavailability of oral progesterone, there is high interindividual variability in the formation and levels of allopregnanolone and pregnanolone with oral progesterone. As a result, some individuals may experience considerable central depressant effects with oral progesterone, whereas others may experience minimal such effects. With oral administration of progesterone, allopregnanolone and pregnanolone circulate at higher concentrations than progesterone.
=== 20 February === Ten people were killed in an airstrike in El Khazan Jadeed, East Darfur. The Sudanese government recalled its ambassador to Kenya over the latter's hosting of meetings by the RSF and allied groups. It also imposed a ban on the Saudi-owned Asharq News news channel, which was lifted on 24 March.
The Centers for Medicare & Medicaid Services (CMS) is a federal agency within the United States Department of Health and Human Services (HHS) that administers the Medicare program and works in partnership with state governments to administer Medicaid, the Children's Health Insurance Program (CHIP), and health insurance portability standards. In addition to these programs, CMS has other responsibilities, including the administrative simplification standards from the Health Insurance Portability and Accountability Act of 1996 (HIPAA), quality standards in long-term care facilities (more commonly referred to as nursing homes) through its survey and certification process, clinical laboratory quality standards under the Clinical Laboratory Improvement Amendments, and oversight of HealthCare.gov. CMS was previously known as the Health Care Financing Administration (HCFA) until 2001. CMS actively inspects and reports on every nursing home in the United States. This includes maintaining the 5-Star Quality Rating System.
=== Elderly === A 2006 review regarding the management of insomnia and the elderly found that considerable evidence of the effectiveness and lasting benefits of nondrug treatments for insomnia exist. Compared with the benzodiazepines, the nonbenzodiazepine sedative-hypnotics offer few if any advantages in efficacy or tolerability in elderly persons. Other agents such as the melatonin receptor agonists may be more suitable and effective for the management of chronic insomnia in elderly people. Long-term use of sedative-hypnotics for insomnia lacks an evidence base and is discouraged for reasons that include concerns about such potential adverse drug effects as cognitive impairment (anterograde amnesia), daytime sedation, motor incoordination, and increased risk of motor vehicle accidents and falls.
Sources: en.wikipedia.org
=== Quantitative proteomics === A central theme of Borchers' work is the use of multiple reaction monitoring (MRM) mass spectrometry with stable isotope-labelled internal standard peptides to measure the absolute concentrations of proteins in complex biological samples such as blood plasma and tissues. His groups developed standardized, multiplexed LC-MRM assay panels for the quantitation of large numbers of proteins, characterizing them according to the assay-validation guidelines of the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC). He was among the authors of a 2009 CPTAC multi-laboratory study in Nature Biotechnology that assessed the reproducibility, dynamic range and detection limits of MRM-based protein measurements across laboratories and instrument platforms. In a 2024 study, his group and collaborators designed and validated MRM assays for the quantitation of 2,118 proteins across 20 mouse organs and tissues, releasing the assays and reference data through an open-access database called MouseQuaPro. He also worked on immuno-MALDI (iMALDI), a method that couples antibody-based enrichment of target peptides with MALDI mass spectrometry to quantify low-abundance proteins in clinical samples. He is the named inventor on a United States patent covering the underlying quantitation method, filed in 2003, granted in 2010 and assigned to the University of North Carolina at Chapel Hill.
==== Lists of nidanas ==== In the early Buddhist texts, dependent origination is analyzed and expressed in various lists of dependently originated phenomena (dhammas) or causes (nidānas). Nidānas are co-dependent principles, processes or events, which act as links on a chain, conditioning and depending on each other. When certain conditions are present, they give rise to subsequent conditions, which in turn give rise to other conditions. Phenomena are sustained only so long as their sustaining factors remain. The most common one is a list of twelve causes (Pali: dvādasanidānāni, Sanskrit: dvādaśanidānāni). Bucknell refers to it as the "standard list". It is found in section 12 of the Samyutta Nikaya and its parallels, as well as in other suttas belonging to other Nikayas and Agamas. This list also appears in Mahasamghika texts like the Salistamba Sutra and in (later) works like Abhidharma texts and Mahayana sutras. According to Eviatar Shulman, "the 12 links are paticcasamuppada," which is a process of mental conditioning. Cox notes that even though the early scriptures contain numerous variations of lists, the 12 factor list became the standard list in the later Abhidharma and Mahayana treatises. The most common interpretation of the twelve cause list in the traditional exegetical literature is that the list is describing the conditional arising of rebirth in saṃsāra, and the resultant duḥkha (suffering, pain, unsatisfactoriness).
=== Diabetes mellitus === Diabetes mellitus (DM) is an immune-disease characterized by the presence of hyperglycemia. Typically these symptoms are brought about by insulin deficiency. However, there have been many recent articles alluding to a correlation between hsp70, in some cases hsp60, and DM. Another recent article discovered the ratio of ehsp70 and ihsp70 could have an effect on DM, leading to a sufficient biomarker. Serum levels of hsp70 have also been shown to increase over time in patients with diabetes.
Sources: en.wikipedia.org
The open spaces of areolar connective tissue, a type of loose connective tissue Areolae (diatom), pores in the silica shell of diatoms Areole, a raised structure bearing spines on cacti Areola (lichen), a round to polygonal part of a surface of a crustose lichen Areola (entomology), a small ring of color or gap in wing margin of insects- see the Glossary of entomology terms. Areola, the open space created by higher venation of a leaf - see the Glossary of botanical terms
When exposed to low oxygen concentrations, haemoglobin S polymerises into long strands within red blood cells (RBCs). These strands distort the shape of the cell and, after a few seconds, cause it to adopt an abnormal, inflexible, sickle-like shape. This process reverses when oxygen concentration is raised, and the cells resume their normal biconcave disc shape. If sickling takes place in the venous system, after blood has passed through the capillaries, it does not affect the organs, and the RBCs can unsickle when they become oxygenated in the lungs. Repeated switching between sickle and normal shapes damages the membrane of the RBC so that it eventually becomes permanently sickled. Normal red blood cells are quite elastic and have a biconcave disc shape, which allows the cells to deform to pass through capillaries. In sickle cell disease, low oxygen tension promotes red blood cell sickling and repeated sickling episodes damage the cell membrane and decrease the cell's elasticity. These cells fail to return to normal shape when oxygen tension is restored. As a consequence, these rigid blood cells are unable to deform as they pass through narrow capillaries, leading to vessel occlusion and ischaemia. Sickled cells are detected as they pass through the spleen and are destroyed. In young children with sickle cell disease, the accumulation of sickled cells in the spleen can result in splenic sequestration crisis. In this, the spleen becomes engorged with blood, depriving the general circulation of blood cells and leading to severe anaemia.
Location of action The central location of action (effect) of the fat cell-specific hormone leptin is the hypothalamus, a part of the brain and thus of the central nervous system. Non-hypothalamic targets of leptin are referred to as peripheral targets. There is a different relative importance of central and peripheral leptin interactions under different physiologic states, and variations among species. Mode of action Leptin acts directly on leptin receptors in the cell membrane of different types of cells in the human body in particular, and in vertebrates in general. The leptin receptor is found on a wide range of cell types. It is a single-transmembrane-domain type I cytokine receptor, a special class of cytokine receptors. Further, leptin interacts with other hormones and energy regulators, indirectly mediating the effects of: insulin, glucagon, insulin-like growth factor, growth hormone, glucocorticoids, cytokines, and metabolites. Function The primary function of the hormone leptin is the regulation of adipose tissue mass through central hypothalamus mediated effects on hunger, food energy use, physical exercise, and energy balance. Outside the brain, in the periphery of the body, leptin's secondary functions are: modulation of energy expenditure, modulation between fetal and maternal metabolism, and that of a permissive factor in puberty, activator of immune cells, activator of beta islet cells, and growth factor.
In this flow regime, many small vortices are responsible for the transfer of momentum between the bulk of the fluid to the pipe wall. As the friction Reynolds number Re√fD increases, the profile of the fluid velocity approaches the wall asymptotically, thereby transferring more momentum to the pipe wall, as modeled in Blasius boundary layer theory.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.